Susan Green developed a stubborn cough in December 2023. Nearly two years after contracting respiratory syncytial virus, or ...

Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...

RSV vaccines were 58% effective at preventing RSV-associated hospitalizations among adults age 60 or older across two seasons. Vaccine effectiveness against all-cause cardiorespiratory ...

June 17, 2025 – The FDA has expanded the use of Moderna's respiratory syncytial virus (RSV) shot to all adults, with some limits on who can get it. First approved in 2024 for people 60 or older, the ...

Bismarck health officials are cautioning residents to take preventative steps as flu, COVID-19 and other respiratory viruses are expected to circulate more widely in the coming months.

New real-world data confirm the RSV vaccine offers strong protection for older adults across two winters, but highlight weaker responses in those with compromised immunity and cardiovascular disease.

The winter respiratory virus season is still in full swing, with Illinois under a “high” alert level from the Centers for Disease Control and Prevention. Among the viruses circulating most are ...

Approximately 1 in 20 adults with outpatient respiratory syncytial virus (RSV) infections were readmitted to the hospital within 28 days, based on new data from more than 67,000 cases. RSV remains a ...

"This study includes CDC’s first comprehensive estimates of RSV disease burden in U.S. adults, including hospitalizations and in-hospital deaths. It demonstrates that RSV caused a substantial burden ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in adults ...

ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower ...